Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY, et al. Circulating tumor cells: clinical validity and utility. Int J Clin Oncol. 2017;22:421–30.
Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6:479–91.
Wang H, Stoecklein NH, Lin PP, Gires O. Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion. Oncotarget. 2017;8:1884–912.
Francart ME, Lambert J, Vanwynsberghe AM, Thompson EW, Bourcy M, Polette M, et al. Epithelial-mesenchymal plasticity and circulating tumor cells: travel companions to metastases. Dev Dyn. 2018;247:432–50.
Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29:212–26.
Jolly MK, Somarelli JA, Sheth M, Biddle A, Tripathi SC, Armstrong AJ, et al. Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharmacol Ther. 2019;194:161–84.
Alix-Panabieres C, Mader S, Pantel K. Epithelial-mesenchymal plasticity in circulating tumor cells. J Mol Med. 2017;95:133–42.
Markiewicz A, Zaczek AJ. The landscape of circulating tumor cell research in the context of epithelial-mesenchymal transition. Pathobiology. 2017;84:264–83.
Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580–4.
Ruf W, Rothmeier AS, Graf C. Targeting clotting proteins in cancer therapy—progress and challenges. Thromb Res. 2016;140 Suppl 1:S1–7.
Unlu B, Versteeg HH. Cancer-associated thrombosis: the search for the holy grail continues. Res Pract Thromb Haemost. 2018;2:622–9.
Hisada Y, Mackman N. Tissue factor and cancer: regulation, tumor growth, and metastasis. Semin Thromb Hemost. 2019;45:385–95.
Bystricky B, Reuben JM, Mego M. Circulating tumor cells and coagulation-minireview. Crit Rev Oncol Hematol. 2017;114:33–42.
Mitrugno A, Tormoen GW, Kuhn P, McCarty OJ. The prothrombotic activity of cancer cells in the circulation. Blood Rev. 2016;30:11–9.
Beinse G, Berger F, Cottu P, Dujaric ME, Kriegel I, Guilhaume MN, et al. Circulating tumor cell count and thrombosis in metastatic breast cancer. J Thromb Haemost. 2017;15:1981–8.
Mego M, De Giorgi U, Broglio K, Dawood S, Valero V, Andreopoulou E, et al. Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer. 2009;101:1813–6.
Gil-Bernabe AM, Lucotti S, Muschel RJ. Coagulation and metastasis: what does the experimental literature tell us? Br J Haematol. 2013;162:433–41.
Palumbo JS. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost. 2008;34:154–60.
Garnier D, Milsom C, Magnus N, Meehan B, Weitz J, Yu J, et al. Role of the tissue factor pathway in the biology of tumor initiating cells. Thromb Res. 2010;125 Suppl 2:S44–S50.
Ruf W, Riewald M. Regulation of tissue factor expression. In: Madame Curie Bioscience Database. Austin (TX): Landes Bioscience; 2013. https://www.ncbi.nlm.nih.gov/books/NBK6620/.
Bourcy M, Suarez-Carmona M, Lambert J, Francart ME, Schroeder H, Delierneux C, et al. Tissue factor induced by epithelial-mesenchymal transition triggers a procoagulant state that drives metastasis of circulating tumor cells. Cancer Res. 2016;76:4270–82.
Zhang X, Li Q, Zhao H, Ma L, Meng T, Qian J, et al. Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma. Oncotarget. 2017;8:59086–102.
Zhao X, Cheng C, Gou J, Yi T, Qian Y, Du X, et al. Expression of tissue factor in human cervical carcinoma tissue. Exp Ther Med. 2018;16:4075–81.
Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer. 2000;83:164–70.
Theunissen JW, Cai AG, Bhatti MM, Cooper AB, Avery AD, Dorfman R, et al. Treating tissue factor-positive cancers with antibody-drug conjugates that do not affect blood clotting. Mol Cancer Ther. 2018;17:2412–26.
Breij EC, de Goeij BE, Verploegen S, Schuurhuis DH, Amirkhosravi A, Francis J, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res. 2014;74:1214–26.
Hu Z, Xu J, Cheng J, McMichael E, Yu L, Carson WE 3rd. Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer. Oncotarget. 2017;8:1481–94.
Aberg M, Siegbahn A. Tissue factor non-coagulant signalling - molecular mechanisms and biological consequences with focus on cell migration and apoptosis. J Thromb Haemost. 2013;11:817–25.
Rothmeier AS, Liu E, Chakrabarty S, Disse J, Mueller BM, Ostergaard H, et al. Identification of the integrin-binding site on coagulation factor VIIa required for proangiogenic PAR2 signaling. Blood. 2018;131:674–85.
Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007;110:133–41.
Liu S, Zhang Y, Zhao X, Wang J, Di C, Zhao Y, et al. Tumor-specific silencing of tissue factor suppresses metastasis and prevents cancer-associated hypercoagulability. Nano Lett. 2019;19:4721–30.
Biggerstaff JP, Weidow B, Dexheimer J, Warnes G, Vidosh J, Patel S, et al. Soluble fibrin inhibits lymphocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis and immunotherapy. Clin Appl Thromb Hemost. 2008;14:193–202.
Lowery J, Kuczmarski ER, Herrmann H, Goldman RD. Intermediate filaments play a pivotal role in regulating cell architecture and function. J Biol Chem. 2015;290:17145–53.
Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68:989–97.
Dauphin M, Barbe C, Lemaire S, Nawrocki-Raby B, Lagonotte E, Delepine G, et al. Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas. Lung Cancer. 2013;81:117–22.
Yamashita N, Tokunaga E, Kitao H, Hisamatsu Y, Taketani K, Akiyoshi S, et al. Vimentin as a poor prognostic factor for triple-negative breast cancer. J Cancer Res Clin Oncol. 2013;139:739–46.
Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson EW, Noel A, et al. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene. 2012;31:3741–53.
Satelli A, Batth IS, Brownlee Z, Rojas C, Meng QH, Kopetz S, et al. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Sci Rep. 2016;6:28910.
Gilles C, Polette M, Zahm JM, Tournier JM, Volders L, Foidart JM, et al. Vimentin contributes to human mammary epithelial cell migration. J Cell Sci. 1999;112:4615–25.
Sun BO, Fang Y, Li Z, Chen Z, Xiang J. Role of cellular cytoskeleton in epithelial-mesenchymal transition process during cancer progression. Biomed Rep. 2015;3:603–10.
Sutoh Yoneyama M, Hatakeyama S, Habuchi T, Inoue T, Nakamura T, Funyu T, et al. Vimentin intermediate filament and plectin provide a scaffold for invadopodia, facilitating cancer cell invasion and extravasation for metastasis. Eur J Cell Biol. 2014;93:157–69.
Matrone MA, Whipple RA, Balzer EM, Martin SS. Microtentacles tip the balance of cytoskeletal forces in circulating tumor cells. Cancer Res. 2010;70:7737–41.
Wang W, Yi M, Zhang R, Li J, Chen S, Cai J, et al. Vimentin is a crucial target for anti-metastasis therapy of nasopharyngeal carcinoma. Mol Cell Biochem. 2018;438:47–57.
Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68:3033–46.
Ivaska J. Vimentin: Central hub in EMT induction? Small GTPases. 2011;2:51–3.
Dmello C, Sawant S, Alam H, Gangadaran P, Tiwari R, Dongre H, et al. Vimentin-mediated regulation of cell motility through modulation of beta4 integrin protein levels in oral tumor derived cells. Int J Biochem Cell Biol. 2016;70:161–72.
Virtakoivu R, Mai A, Mattila E, De Franceschi N, Imanishi SY, Corthals G, et al. Vimentin-ERK signaling uncouples slug gene regulatory function. Cancer Res. 2015;75:2349–62.
Perlson E, Michaelevski I, Kowalsman N, Ben-Yaakov K, Shaked M, Seger R, et al. Vimentin binding to phosphorylated Erk sterically hinders enzymatic dephosphorylation of the kinase. J Mol Biol. 2006;364:938–44.
Phua DC, Humbert PO, Hunziker W. Vimentin regulates scribble activity by protecting it from proteasomal degradation. Mol Biol Cell. 2009;20:2841–55.
Satelli A, Hu J, Xia X, Li S. Potential function of exogenous vimentin on the activation of Wnt signaling pathway in cancer cells. J Cancer. 2016;7:1824–32.
Schmidt Y, Biniossek M, Stark GB, Finkenzeller G, Simunovic F. Osteoblastic alkaline phosphatase mRNA is stabilized by binding to vimentin intermediary filaments. Biol Chem. 2015;396:253–60.
Li S, Chen H, Ren J, Geng Q, Song J, Lee C, et al. MicroRNA-223 inhibits tissue factor expression in vascular endothelial cells. Atherosclerosis. 2014;237:514–20.
Witkowski M, Tabaraie T, Steffens D, Friebel J, Dorner A, Skurk C, et al. MicroRNA-19a contributes to the epigenetic regulation of tissue factor in diabetes. Cardiovasc Diabetol. 2018;17:34.
Yu YH, Wu DS, Huang FF, Zhang Z, Liu LX, Zhang J, et al. MicroRNA-20b and ERK1/2 pathway independently regulate the expression of tissue factor in hematopoietic and trophoblastic differentiation of human embryonic stem cells. Stem Cell Res Ther. 2013;4:121.
D’Asti E, Huang A, Kool M, Meehan B, Chan JA, Jabado N, et al. Tissue factor regulation by miR-520g in primitive neuronal brain tumor cells: a possible link between oncomirs and the vascular tumor microenvironment. Am J Pathol. 2016;186:446–59.
Zhang X, Yu H, Lou JR, Zheng J, Zhu H, Popescu NI, et al. MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem. 2011;286:1429–35.
Yu G, Li H, Wang X, Wu T, Zhu J, Huang S, et al. MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion. Mol Cell Biochem. 2013;380:239–47.
D’Asti E, Rak J. Biological basis of personalized anticoagulation in cancer: oncogene and oncomir networks as putative regulators of coagulopathy. Thromb Res. 2016;140 Suppl 1:S37–43.
Eisenreich A, Leppert U. The impact of microRNAs on the regulation of tissue factor biology. Trends Cardiovasc Med. 2014;24:128–32.
Agarwal V, Bell GW, Nam JW, Bartel DP Predicting effective microRNA target sites in mammalian mRNAs. Elife 2015;4:e05005.
Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43:D146–52.
Magnus N, D’Asti E, Meehan B, Garnier D, Rak J. Oncogenes and the coagulation system – forces that modulate dormant and aggressive states in cancer. Thromb Res. 2014;133:S1–S9.
Provencal M, Labbe D, Veitch R, Boivin D, Rivard GE, Sartelet H, et al. c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration. Carcinogenesis. 2009;30:1089–96.
Milsom CC, Yu JL, Mackman N, Micallef J, Anderson GM, Guha A, et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Res. 2008;68:10068–76.
de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:383–93.
Milsom C, Magnus N, Meehan B, Al-Nedawi K, Garnier D, Rak J. Tissue factor and cancer stem cells: is there a linkage? Arterioscler Thromb Vasc Biol. 2009;29:2005–14.
Aa Challa, B. Stefanovic. A novel role of vimentin filaments: binding and stabilization of collagen mRNAs. Mol Cell Biol. 2011;31:3773–89.
Song KY, Choi HS, Law PY, Wei LN, Loh HH. Vimentin interacts with the 5’-untranslated region of mouse mu opioid receptor (MOR) and is required for post-transcriptional regulation. RNA Biol. 2013;10:256–66.
Chatterjee S, Panda AC, Berwal SK, Sreejith RK, Ritvika C, Seshadri V, et al. Vimentin is a component of a complex that binds to the 5’-UTR of human heme-regulated eIF2alpha kinase mRNA and regulates its translation. FEBS Lett. 2013;587:474–80.
Witkowski M, Weithauser A, Tabaraie T, Steffens D, Krankel N, Witkowski M, et al. Micro-RNA-126 reduces the blood thrombogenicity in diabetes mellitus via targeting of tissue factor. Arterioscler Thromb Vasc Biol. 2016;36:1263–71.
Teruel R, Perez-Sanchez C, Corral J, Herranz MT, Perez-Andreu V, Saiz E, et al. Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost. 2011;9:1985–92.
Ackland ML, Newgreen DF, Fridman M, Waltham MC, Arvanitis A, Minichiello J, et al. Epidermal growth factor-induced epithelio-mesenchymal transition in human breast carcinoma cells. Lab Investig. 2003;83:435–48.
